Phaseline

Companies › Aegle Therapeutics

Aegle Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AGLE-102
Extracellular vesicles derived from bone marrow-derived mesenchymal stem cells
–Phase 1Dystrophic Epidermolysis Bullosa–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04173650AGLE-102Phase 1Dystrophic Epidermolysis BullosaOtherSep 2025

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.